NorthWest Biotherapeutics Inc (NWBO)

[maverick_1]

Thanks Longfellow95, & kabunushi for the needed REDIRECT from financial living on the EDGE towards the 2nd European edition of Phacilitate’s Cell & Gene Therapy 9/21+ Berlin event where the first was a sell-out success in 2015, and here are some of the comments from attendees of the inaugural event:

"Indeed, I found the meeting outstanding and have no negative points (quite unusual for a regulator). Thank you for your outstanding organizational support."
Dr Ralf Sanzenbacher, Deputy Head of Section, Tissue-Engineering & Cell Therapeutics, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines Germany
"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."
Bertrand Alexandre, Director, Marketing Europe, Celyad

The Host Partner German Society for Regenerative Medicine

It is the objective of the German Society for Regenerative Medicine (GRM) to establish the dialogue between researchers and scientists, politicians and the media on this promising field in medicine, to offer a neutral platform for discussion, and to further public understanding of this still controversial topic.

http://www.cgteurope.com/Content/Immunotherapy-Agenda/4_17/

DRIVING INCREASED PHARMA AND VC INVESTMENT IN EUROPEAN IMMUNOTHERAPY

Following 08:45 - 09:10
CHAIR'S INTRODUCTION
Setting the scene: Analysing key successes and failures for European immunotherapy in 2015/16
What have been the key deals and collaborations in Europe over the past 12 months?
Where can we expect the biggest breakthrough stories to come from in immuno-oncology?

[b[color=red]]KEY Question: Who will be presenting in 2nd presentation 9/21@ 9:10 AM (UNDER WRAPS)
following[/color]

MD1225:

Wow thank you Longfellow for posting links I was aware of the conference but not the major role Linda is playing!

NOT evident, unless I overlooked? what CEO LP's major role UNLESS CEO LP is doing the 2nd presentation spot!PERHAPS a MILESTONE may be set: A BMY CI deal? but until who is presenting in that 2nd spot with a title of presentation is confirmed: CEO LP is just an attendee like last year under Cognate BioServices.

Notice that 2015 Attendees:
COGNATE BIOSERVICES
Catapult Cell Therapy see:http://investorshub.advfn.com/boards/read_msg.aspx?message_id=123374786

2. UK Groundbreaking Nov 2015 with 2017 completion of ~$60+Mln COST of Catapult's NEW Regenerative Cell Mfg.

The Cell and Gene Therapy Catapult is part of a family of Catapults which are not-for profit, independent centres which connect businesses with the UK’s research and academic communities.

https://ct.catapult.org.uk/news-events-gallery/news/new-report-shows-capacity-capability-cell-gene-therapy-manufacturing-continues-increase-uk/

https://ct.catapult.org.uk/manufacturing/manufacturing-centre-status-updates/

AND logically one can see why Donnie McGrath as one of BMY's representatives present would be presenting his:

22 Sep 2016 08:50 - 09:05AM
How Emerging Science Will Evolve Partnerships for Immuno-Oncology Combination Therapies

since BMY's Opdvio overshadows that of Yervoy and even MRK's Keytruda in Combo deals.BMY's most recent Opdivo deals was Cormorant for $520 mln: http://www.businesswire.com/news/home/20160705005037/en/Bristol-Myers-Squibb-Acquires-Cormorant-Pharmaceuticals
One only needs to look at the history and frequency of BMY/Opdivo deals.